Clinical trials: Malignancies Multiple
Carcinoma, Non-Small-Cell Lung
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
This is a phase II, single institution trial for patients with clinical Stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable lung tumors.
- Trial name
- NCT00130780
- Testing
- Pre-surgical Treatment with Bevacizumab plus Chemotherapy, Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899080
- Testing
- gene expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Eastern Cooperative Oncology Group
Multiple Myeloma
Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
This is a multicenter, open-label phase II study, assessing the efficacy of elotuzumab in elderly patients with multiple myeloma undergoing peripheral stem cell autologous graft
- Trial name
- IFM2016-03 (NCT03393273)
- Testing
- Elotuzumab
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematologic Neoplasms, Leukemia
Musculoskeletal Ultrasound in Patients With Hematologic Malignancies
This study evaluates the role and diagnostic value of musculoskeletal ultrasonography (MSUS) in adult patients with hematologic malignancies who present with musculoskeletal symptoms.
- Conditions
- Hematologic Neoplasms, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT07785505
- Volunteers
- 50 people
- Sponsor
- Assiut University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ALK rearrangement.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439266
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic or Locally Advanced Solid Tumors
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
The purpose of the trial is to determine the maximum tolerated dose (MTD) of BEZ235 and BKM120 in combination with weekly paclitaxel and weekly paclitaxel/trastuzumab.
- Trial name
- NCT01285466
- Testing
- BEZ235 + paclitaxel, BKM120 + paclitaxel, BEZ235 + paclitaxel + trastuzumab
- Where
- 10 sites in Belgium, Germany and 3 more
- Volunteers
- 110 people
- Sponsor
- Novartis Pharmaceuticals
Malignancy, Hematologic, Neoplasms, Hematologic
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes.
- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer
- Trial name
- NCT06904066
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration.
- Trial name
- NCT05561751
- Testing
- GPC-100, Propranolol, G-CSF
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- GPCR Therapeutics, Inc.
Colorectal Cancer
Prognosis Stratification for pT4bN0M0 Colorectal Cancer Following Multivisceral Resection
The purpose of this study was to identify the prognostic factors of affecting pT4bN0M0 colorectal cancer patients, so as to better stratify the prognostic differences among patients with the same stage.
- Trial name
- NCT06115837
- Testing
- multivisceral resection
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Carcinoma, Renal Cell
A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes
This is a Phase I study to determine the effect of GW786034 (pazopanib) on P450 enzymes. This study will help determine which types of drugs may interact with GW786034.
- Trial name
- NCT00401583
- Testing
- GW786034 (pazopanib), Probe drugs
- Where
- 2 sites in United States, Singapore
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Lymphadenopathy, Lymphnode Metastasis
Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
Lymph nodes are one of the most important components of the human immune system, and superficial lymph node enlargement lacks specificity.
- Conditions
- Lymphadenopathy, Lymphnode Metastasis, Lymphoma, Lymphatic Tuberculosis
- Trial name
- NCT07155954
- Testing
- SRUS imaging of the lymph nodes before surgery or biopsy
- Where
- China
- Volunteers
- 779 people
- Sponsor
- Peking University Third Hospital
Tumors Metastatic to Brain
Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
Randomized phase III trial to compare the effectiveness of radiation therapy with or without thalidomide in treating patients who have brain metastases. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033254
- Testing
- radiation therapy, thalidomide, quality-of-life assessment
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, T(11;14)
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
This phase I trial studies the side effects and best dose of venetoclax when given together with ixazomib citrate and dexamethasone and to see how well they work in treating patients with multiple myeloma that has come back.
- Trial name
- NCT03399539
- Testing
- Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.
- Trial name
- MAGNETISMM17 (NCT05462639)
- Testing
- Elranatamab (PF-06863135)
- Where
- 36 sites in United States, Canada
- Sponsor
- Pfizer
Multiple Myeloma
Optical Genome Mapping in Characterization of Multiple Myeloma
The current cytogenetic characterization of Multiple Myeloma (including chromosome and gene abnormalities identification in abnormal plasma cells) encounters some limitations.
- Trial name
- MYELOPTIC (NCT05786105)
- Testing
- Bone Marrow samples collection
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Solid Tumors
MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.
The purpose of this study is to evaluate the safety and tolerability of MASCT-I in patients with metastatic or recurrent solid tumors who failed standard therapy.
- Trial name
- NCT05877651
- Testing
- MASCT-I injection
- Where
- China
- Volunteers
- 22 people
- Sponsor
- HRYZ Biotech Co.
Vertebral Fracture, Multiple Myeloma
Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.
Balloon Kyphoplasty is an alternative to vertebroplasty in the treatment of painful malignant vertebral fractures. This is a mini-invasive percutaneous treatment, aiming to stabilize the vertebral fracture, decrease of pain.
- Conditions
- Vertebral Fracture, Multiple Myeloma, Osteolytic Metastases
- Trial name
- KYPHOK (NCT00748631)
- Testing
- balloon kyphoplasty
- Where
- 4 sites in France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-small Cell Lung Cancer, Neoantigen
Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)
This multicenter prospective observational and exploratory study aims to develop and validate a novel multi-omics-based computational method for neoantigen prediction in non-small cell lung cancer (NSCLC), and discover biomarkers…
- Conditions
- Non-small Cell Lung Cancer, Neoantigen, Next-generation Sequencing, Biomarker
- Trial name
- MOTIVATION (NCT04923802)
- Where
- China
- Volunteers
- 13 people
- Sponsor
- GeneCast Biotechnology Co., Ltd.
Lung Neoplasms
Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
Primary Objective: To evaluate the toxicity/safety profile of docetaxel/cisplatin induction therapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by consolidation docetaxel/cisplatin in…
- Trial name
- NCT00174772
- Testing
- docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy, docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin
- Where
- 8 sites in Belgium, Finland and 6 more
- Volunteers
- 72 people
- Sponsor
- Sanofi
Tumors
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
- Trial name
- NCT02549937
- Testing
- surufatinib
- Where
- 12 sites in United States, Italy
- Volunteers
- 130 people
- Sponsor
- Hutchmed
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.